Buprenorphine Extended-Release in Jail and at Re-Entry: Pilot Proof-of-Concept Versus Daily Sublingual Buprenorphine-Naloxone
Extended-release buprenorphine (XR-B) is newly FDA approved and its effectiveness in a criminal justice setting is promising but untested. This is an ongoing 8-week pilot proof-of-concept randomized controlled trial, open-label and unblinded, examining the feasibility and acceptability of XR-B versus daily sublingual buprenorphine-naloxone (SL-B) for the treatment of opioid use disorder in jail and at community re-entry.
XR-B has several potential advantages versus SL-B, notably the near zero probability of diversion and an improved, long-acting “bridge” of medication adherence at release. So far, XR-B has shown promising rates of retention in a vulnerable population.
This study is supported by the National Institute on Drug Abuse (NCT03604159).